Part 7/8:
While challenges remain—especially concerning the reimbursement landscape—expert opinions suggest that the CAR-T market may gradually shift towards a more positive trajectory. Although sales may grow more slowly than originally hoped, the accumulation of encouraging clinical data and responsiveness from stakeholders could lead to steady momentum for CAR-T stocks in the years to come.